Extinction models for cancer stem cell therapy.

Cells with stem cell-like properties are now viewed as initiating and sustaining many cancers. This suggests that cancer can be cured by driving these cancer stem cells to extinction. The problem with this strategy is that ordinary stem cells are apt to be killed in the process. This paper sets bounds on the killing differential (difference between death rates of cancer stem cells and normal stem cells) that must exist for the survival of an adequate number of normal stem cells. Our main tools are birth-death Markov chains in continuous time. In this framework, we investigate the extinction times of cancer stem cells and normal stem cells. Application of extreme value theory from mathematical statistics yields an accurate asymptotic distribution and corresponding moments for both extinction times. We compare these distributions for the two cell populations as a function of the killing rates. Perhaps a more telling comparison involves the number of normal stem cells NH at the extinction time of the cancer stem cells. Conditioning on the asymptotic time to extinction of the cancer stem cells allows us to calculate the asymptotic mean and variance of NH. The full distribution of NH can be retrieved by the finite Fourier transform and, in some parameter regimes, by an eigenfunction expansion. Finally, we discuss the impact of quiescence (the resting state) on stem cell dynamics. Quiescence can act as a sanctuary for cancer stem cells and imperils the proposed therapy. We approach the complication of quiescence via multitype branching process models and stochastic simulation. Improvements to the τ-leaping method of stochastic simulation make it a versatile tool in this context. We conclude that the proposed therapy must target quiescent cancer stem cells as well as actively dividing cancer stem cells. The current cancer models demonstrate the virtue of attacking the same quantitative questions from a variety of modeling, mathematical, and computational perspectives.

[1]  Max S Wicha,et al.  Cancer stem cells: an old idea--a paradigm shift. , 2006, Cancer research.

[2]  O. Okamoto,et al.  Targeting cancer stem cells with monoclonal antibodies: a new perspective in cancer therapy and diagnosis , 2008, Expert review of molecular diagnostics.

[3]  S. Karlin,et al.  LINEAR GROWTH, BIRTH AND DEATH PROCESSES , 1958 .

[4]  M. Copland,et al.  Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. , 2006, Blood.

[5]  C. Eaves,et al.  Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. , 2001, Blood.

[6]  Kenneth Lange,et al.  In the Garden of Branching Processes , 2004, SIAM Rev..

[7]  Sean J. Morrison,et al.  Asymmetric and symmetric stem-cell divisions in development and cancer , 2006, Nature.

[8]  A. Bhandoola,et al.  Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss. , 2007, Cell stem cell.

[9]  D. Gillespie.  Exact Stochastic Simulation of Coupled Chemical Reactions , 1977 .

[10]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[11]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[12]  N. Goulden,et al.  Characterization of acute lymphoblastic leukemia progenitor cells. , 2004, Blood.

[13]  M. Carroll,et al.  Survival of acute myeloid leukemia cells requires PI3 kinase activation. , 2003, Blood.

[14]  C. Jordan.  Can we finally target the leukemic stem cells? , 2008, Best practice & research. Clinical haematology.

[15]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[16]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[17]  Desmond J. Higham,et al.  Modeling and Simulating Chemical Reactions , 2008, SIAM Rev..

[18]  J. Dick,et al.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice , 2007, Nature.

[19]  T. E. Harris,et al.  The Theory of Branching Processes. , 1963 .

[20]  I. Weissman,et al.  In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Kenneth Lange,et al.  Numerical analysis for statisticians , 1999 .

[22]  B. Smith,et al.  Immunotherapy for myeloid leukemias: current status and future directions , 2008, Leukemia.

[23]  Mohamed H. Sayegh,et al.  Identification of cells initiating human melanomas , 2008, Nature.

[24]  Derick R. Peterson,et al.  The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. , 2005, Blood.

[25]  Michael F. Clarke,et al.  Applying the principles of stem-cell biology to cancer , 2003, Nature Reviews Cancer.

[26]  Samuel Karlin,et al.  A First Course on Stochastic Processes , 1968 .

[27]  S. Morrison,et al.  Efficient tumor formation by single human melanoma cells , 2008, Nature.

[28]  Dominik Wodarz,et al.  Drug resistance in cancer: principles of emergence and prevention. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  T. Papayannopoulou,et al.  Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. , 1977, The American journal of medicine.

[30]  S. Morrison,et al.  Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells , 2006, Nature.

[31]  Jeffrey M. Rosen,et al.  The Increasing Complexity of the Cancer Stem Cell Paradigm , 2009, Science.

[32]  Goldie Jh,et al.  Quantitative model for multiple levels of drug resistance in clinical tumors. , 1983 .

[33]  Utpal Banerjee,et al.  The hematopoietic stem cell and its niche: a comparative view. , 2007, Genes & development.

[34]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[35]  K. Lange,et al.  Differential destruction of stem cells: implications for targeted cancer stem cell therapy. , 2009, Cancer research.

[36]  C. Jamieson,et al.  Chronic myeloid leukemia stem cells. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Kenneth Lange,et al.  Accurate Stochastic Simulation via the Step Anticipation τ-Leaping (SAL) Algorithm , 2009, J. Comput. Biol..

[38]  Linda R Petzold,et al.  Efficient step size selection for the tau-leaping simulation method. , 2006, The Journal of chemical physics.

[39]  Catherine M. Verfaillie,et al.  The molecular repertoire of the 'almighty' stem cell , 2005, Nature Reviews Molecular Cell Biology.

[40]  J. Goldie,et al.  Quantitative model for multiple levels of drug resistance in clinical tumors. , 1983, Cancer treatment reports.

[41]  L. Allen.  Stem cells. , 2003, The New England journal of medicine.

[42]  R. McLendon,et al.  Targeting cancer stem cells through L1CAM suppresses glioma growth. , 2008, Cancer research.

[43]  Birth and death processes with absorption , 1992 .

[44]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[45]  Martin A. Nowak,et al.  Dynamics of chronic myeloid leukaemia , 2005, Nature.

[46]  Ronald L. Graham,et al.  Concrete mathematics - a foundation for computer science , 1991 .

[47]  I. Shih,et al.  Notch Signaling, γ-Secretase Inhibitors, and Cancer Therapy: Figure 1. , 2007 .

[48]  P. Cochat,et al.  Et al , 2008, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[49]  E. T. Gawlinski,et al.  A reaction-diffusion model of cancer invasion. , 1996, Cancer research.

[50]  Serik Sagitov,et al.  On the path to extinction , 2007, Proceedings of the National Academy of Sciences.

[51]  L. Hayflick.  THE LIMITED IN VITRO LIFETIME OF HUMAN DIPLOID CELL STRAINS. , 1965, Experimental cell research.

[52]  O. Witte,et al.  The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[53]  D. Ambrosi,et al.  On the mechanics of a growing tumor , 2002 .

[54]  C. Huff,et al.  Characterization of clonogenic multiple myeloma cells. , 2004, Blood.

[55]  P. Henrici.  Fast Fourier Methods in Computational Complex Analysis , 1979 .

[56]  Mark Shackleton,et al.  Efficient tumour formation by single human melanoma cells , 2008 .

[57]  Michael C. Ferris,et al.  Optimizing the Delivery of Radiation Therapy to Cancer Patients , 1999, SIAM Rev..

[58]  Laurie E Ailles,et al.  Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. , 2004, The New England journal of medicine.

[59]  D. Kendall.  Applied Probability , 1958, Nature.

[60]  G. Schuurhuis,et al.  MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia , 2004, Leukemia.

[61]  T. Ferguson.  A Course in Large Sample Theory , 1996 .

[62]  D. Gillespie.  A General Method for Numerically Simulating the Stochastic Time Evolution of Coupled Chemical Reactions , 1976 .

[63]  William Feller,et al.  An Introduction to Probability Theory and Its Applications , 1967 .

[64]  K. Lange,et al.  Mutation Takes No Vacation: Can Structured Treatment Interruptions Increase the Risk of Drug‐Resistant HIV‐1? , 2000, Journal of acquired immune deficiency syndromes.

[65]  S. V. Sotirchos,et al.  Variations in tumor cell growth rates and metabolism with oxygen concentration, glucose concentration, and extracellular pH , 1992, Journal of cellular physiology.

[66]  Marek Kimmel,et al.  Branching processes in biology , 2002 .

[67]  Franziska Michor,et al.  Successful Therapy Must Eradicate Cancer Stem Cells , 2006, Stem cells.

[68]  Feller William,et al.  An Introduction To Probability Theory And Its Applications , 1950 .

[69]  Peter Guttorp,et al.  Evidence that the number of hematopoietic stem cells per animal is conserved in mammals. , 2002, Blood.

[70]  E. Caussinus,et al.  Induction of tumor growth by altered stem-cell asymmetric division in Drosophila melanogaster , 2005, Nature Genetics.

[71]  I. Weissman,et al.  Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma , 2007, Proceedings of the National Academy of Sciences.

[72]  Darren J. Wilkinson.  Stochastic Modelling for Systems Biology , 2006 .

[73]  Ash A. Alizadeh,et al.  CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells , 2009, Cell.

[74]  D. Gillespie.  Approximate accelerated stochastic simulation of chemically reacting systems , 2001 .

[75]  B. Thiers,et al.  Identification of cells initiating human melanomas , 2009 .

[76]  D. Bonnet.  Haematopoietic stem cells 1 , 2002, The Journal of pathology.

[77]  G. Grimmett,et al.  Probability and random processes , 2002 .

[78]  Nicolò Riggi,et al.  Identification of cancer stem cells in Ewing's sarcoma. , 2009, Cancer research.

[79]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[80]  D. Howard,et al.  Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. , 2001, Blood.

[81]  S. Morrison,et al.  The PI-3kinase pathway in hematopoietic stem cells and leukemia-initiating cells: a mechanistic difference between normal and cancer stem cells. , 2008, Blood cells, molecules & diseases.